AOD-9604

Classification

Modified C-terminal fragment of human growth hormone

Approval status

Investigational · Not approved for human use

Research status

Investigational GH-fragment analogue. Not an approved obesity medicine.

Molecular formula

Insufficient reliable evidence identified.

Molecular weight

Insufficient reliable evidence identified.

Sequence

hGH 176–191 analogue with tyrosine substitution (AOD9604)

Primary biological target

Proposed lipolytic signalling distinct from full GH receptor activation. Mechanism not yet fully established as a drug.

Half-life

Insufficient reliable evidence identified.

Routes investigated

Oral (development), Parenteral (research markets)

Human evidence level

C — Limited or early human evidence

An investigational analogue studied historically for obesity. It is not an approved weight-loss medicine in Australia.

Synthetic analogue of the C-terminal fragment of human GH.

Proposed mechanism

Proposed mechanism: AOD9604 was developed to isolate metabolic/lipolytic actions attributed to the GH C-terminus without full GH-receptor growth effects. Mechanism not yet fully established; development did not yield a registered obesity drug.

Clinical development did not establish a favourable enough efficacy/safety package for registration as an obesity medicine.

• Obesity (development)

  C · Limited or early human evidence

  Early human research has examined oral AOD9604 in obesity; it is not an approved therapy.^[1]

Investigational findings are not proven clinical benefits unless an authority has labelled that indication.

Overall human evidence grade: C · Limited or early human evidence

Clinical trials were conducted; the compound did not become a registered obesity medicine. Human evidence is therefore incomplete for therapeutic use.

Animal, cell and in-vitro findings are listed separately from human effects.

Animal lipolysis studies motivated development but are not a basis for consumer use.

This section does not provide personalised medical dosing. Values are those reported in papers or protocols. Animal mg/kg doses are not converted to human doses.

Doses reported in human studies

1. Early oral AOD9604 obesity development

   Dose: Oral milligram range (paper-specific) mg

   Route: Oral in published development

   Frequency: Daily in development protocols

   Duration: Study-specific

   Population: Adults with obesity (development cohorts)

   Purpose: Exploratory weight/metabolic endpoints

   ^[1]

Preclinical / animal study dosing

Insufficient reliable evidence identified.

Development PK is paper-specific; not a PI.

Insufficient modern labelled AE table.

Unknowns. Injectable research-chemical AOD is not the oral development product.

Contraindications. Not for human use outside approved clinical trials. Not for athletes subject to WADA.

Australia — TGA

Not approved as an obesity drug. WADA has separately addressed AOD9604 in sport.

United States — FDA

Not approved.

European Union — EMA

Not approved.

1. [1] Metabolic studies of AOD9604 / hGH fragment analogues in obesity development

   Ng FM / Heffernan M et al. related AOD9604 papers Metabolic studies of AOD9604 / hGH fragment analogues in obesity development Obesity research corpus. 2000. PMID 10945490

   PMID 10945490